Table 2.
Patients were stratified into four groups based on liver fibrosis downstaging according to liver stiffness values. Values were reported according to their Median and Quartile 1–Quartile 3, Me (Q1;Q3). Inter-group differences were evaluated using Mann–Whitney U test. AST: aspartate aminotransferase; ALT: alanine aminotransferase; NS: not statistically significant difference; NE: not evaluated.
| Patients Stratified by Degree of Fibrosis Regression | AST (IU/L) (Baseline) |
ALT (IU/L) (Baseline) |
Platelets (×109/L) (Baseline) |
AST (IU/L) (1-Year after Therapy) |
ALT (IU/L) (1-Year after Therapy) |
Platelets (×109/L) (1-Year after Therapy) |
% Changes in LSM from Baseline |
|---|---|---|---|---|---|---|---|
|
Group 1 (G1) (n = 34) From F4 to F4 |
62 (28.5;85) |
71 (41.5;87) |
97 (80;130) |
26 (20;34) |
18 (14;29.5) |
115 (90;153) |
−14.3% |
|
Group 2 (G2) (n = 9) From F4 to F3 |
70 (51;90) |
82 (52;118) |
152 (140;217) |
21 (19;26.5) |
15 (13;22.5) |
188 (151;239) |
−20% |
|
Group 3 (G3) (n = 30) From F3/4 to F2 |
110 (90;150) |
100 (89;119) |
170 (150;240) |
20 (18;24) |
16 (15;21) |
190 (170;259) |
−37% |
|
Group 4 (G4) (n = 37) From F3/4 to F0-1 |
176 (149;230) |
251 (182;300) |
222 (146;291) |
22 (20;24) |
21 (17;26) |
251 (182;300) |
−57.5% |
| Statistical Significance | |||||||
| Group 1 vs. Group 2 | p = 0.049 | p = 0.043 | p = 0.019 | NS | NS | p = 0.022 | NE |
| Group 1 vs. Group 3 | p = 0.03 | p = 0.001 | p = 0.001 | NS | NS | p < 0.001 | NE |
| Group 1 vs. Group 4 | p < 0.001 | p < 0.001 | p < 0.001 | NS | NS | p < 0.001 | NE |
| Group 2 vs. Group 3 | p = 0.032 | NS | p = 0.047 | NS | NS | NS | NE |
| Group 3 vs. Group 4 | p = 0.028 | p = 0.021 | p = 0.032 | NS | NS | p = 0.039 | NE |